title: Effect of diquafosol tetrasodium eye drop for persistent dry eye after laser in situ keratomileusis.
abstract: OBJECTIVE
  To evaluate the effect of diquafosol tetrasodium (DQS) for the treatment of persistent dry eye after laser in situ keratomileusis (LASIK).
  
  
  METHODS
  Miyata Eye Hospital, Miyazaki, Japan.
  
  
  METHODS
  Noncomparative case series.
  
  
  METHODS
  This prospective study included 30 eyes of 15 patients in whom dry eye had persisted for over 12 months after LASIK, and the symptoms had not improved with artificial tears and sodium hyaluronate treatment. In addition, treatment with DQS 3% eye drops, 6 times a day, was performed for 12 weeks. Best-corrected visual acuity, tear secretion with the Schirmer test, tear break-up time, and fluorescein and lissamine green staining scores on the cornea and conjunctiva were examined before and at 1, 4, and 12 weeks after the addition. A subjective questionnaire of 14 symptoms was also assessed before and 12 weeks after treatment.
  
  
  RESULTS
  The fluorescein and lissamine green staining scores significantly improved over 12 weeks; however, the best-corrected visual acuity and tear secretion did not change. The symptoms of fatigue, dryness, grittiness, discomfort, difficulty in reading, and discomfort within the area of dryness improved after the additional DQS treatment.
  
  
  CONCLUSIONS
  The DQS treatment improved the subjective and objective symptoms of persistent dry eye after LASIK. Increased mucin production because of the addition of DQS probably improved the tear film stability and reduced the symptoms of dry eye in patients who had persistent dry eye after LASIK.
authors.affiliation: *Miyata Eye Hospital, Miyakonojo, Japan; and †Department of Ophthalmology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
authors.forename: Yosai
authors.initials: Y
authors.lastname: Mori
authors.forename: Ryohei
authors.initials: R
authors.lastname: Nejima
authors.forename: Ayami
authors.initials: A
authors.lastname: Masuda
authors.forename: Yoko
authors.initials: Y
authors.lastname: Maruyama
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Minami
authors.forename: Kazunori
authors.initials: K
authors.lastname: Miyata
authors.forename: Shiro
authors.initials: S
authors.lastname: Amano
mesh_terms: D000328:Adult; D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D020731:Keratomileusis, Laser In Situ; D008297:Male; D008875:Middle Aged; D009077:Mucins / Q000378:metabolism; D009883:Ophthalmic Solutions; D011122:Polyphosphates / Q000008:administration & dosage / Q000627:therapeutic use*; D011183:Postoperative Complications; D011379:Prognosis; D011446:Prospective Studies; D058912:Purinergic P2Y Receptor Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D013666:Tears / Q000737:chemistry; D014500:Uracil Nucleotides / Q000008:administration & dosage / Q000627:therapeutic use*; D014792:Visual Acuity / Q000502:physiology
chemical_list: D009077:Mucins; D009883:Ophthalmic Solutions; D011122:Polyphosphates; D058912:Purinergic P2Y Receptor Agonists; D014500:Uracil Nucleotides; C403315:diquafosol